KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Common Equity (2017 - 2025)

Novartis Ag's Common Equity history spans 9 years, with the latest figure at $46.1 billion for Q4 2025.

  • For Q4 2025, Common Equity rose 4.54% year-over-year to $46.1 billion; the TTM value through Dec 2025 reached $46.1 billion, up 4.54%, while the annual FY2025 figure was $46.1 billion, 4.54% up from the prior year.
  • Common Equity for Q4 2025 was $46.1 billion at Novartis Ag, up from $44.1 billion in the prior quarter.
  • Across five years, Common Equity topped out at $67.8 billion in Q4 2021 and bottomed at $44.1 billion in Q4 2024.
  • The 5-year median for Common Equity is $46.8 billion (2023), against an average of $52.9 billion.
  • The largest annual shift saw Common Equity soared 99638.24% in 2021 before it dropped 21.33% in 2023.
  • A 5-year view of Common Equity shows it stood at $67.8 billion in 2021, then decreased by 12.38% to $59.4 billion in 2022, then fell by 21.33% to $46.8 billion in 2023, then decreased by 5.61% to $44.1 billion in 2024, then grew by 4.54% to $46.1 billion in 2025.
  • Per Business Quant, the three most recent readings for NVS's Common Equity are $46.1 billion (Q4 2025), $44.1 billion (Q4 2024), and $46.8 billion (Q4 2023).